Dr. Zheng brings to AceLink an extensive experience in drug research and development. She obtained a Bachelor of Science degree in Microbiology from Fudan University, and earned PhD in Molecular Microbiology and Immunology from University of Missouri-Columbia. With a research fellowship from NIH, she completed postdoctoral training at University of Missouri-Columbia, focusing on yeast genetics and cell cycle regulation. She then joined Zen Sun Biological Inc, Shanghai, China, a start-up company focusing on developing new drugs for cancer and cardiovascular disease, acting as Director of R&D, responsible for building Company’s R&D center from ground zero and taking the drug candidate Neuregulin for IND filing. She then took the position of Senior Director of R&D at IgCon Therapeutic, Shanghai, China, a start-up company utilizing the proprietary yeast two hybrid platform and library to identify antibody leads for therapeutic uses and to generate high affinity humanized antibodies. In recent years, she has been working as chief consultant with Rightway Consulting Inc., shanghai, China, specializing in regulatory consultation and medical writing in clinical and health-related areas. Several major accomplishments included Ph3 multi-center efficacy and safety trial reports (kidney disease), Ph4 efficacy and safety study (inflammatory disease), Ph3 clinical trial and NDA Registration package (vaccine).
© Copyright AceLink Therapeutics. All rights reserved